Iloprost attenuates the increased permeability in skeletal muscle after ischemia and reperfusion

J Blebea1, R A Cambria, D DeFouw

  • 1Department of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark.

Insights

Iloprost, a prostacyclin analog, significantly reduces increased vascular permeability following skeletal muscle ischemia and reperfusion. This finding supports iloprost

Area of Science:

  • Vascular Biology
  • Ischemia-Reperfusion Injury
  • Pharmacology

Background:

  • Increased vascular permeability is an early indicator of ischemic muscle injury.
  • Prostacyclin analogs may modulate microvascular responses to ischemia.

Purpose of the Study:

  • To investigate the effect of iloprost on microvascular permeability in a rat striated muscle model after ischemia and reperfusion.

Main Methods:

  • Rat cremaster muscle subjected to 2 hours ischemia and 2 hours reperfusion.
  • Iloprost (0.5 microgram/kg/min) administered via continuous intravenous infusion.
  • Fluorescein-labeled dextran used to measure macromolecular tracer clearance and assess microvascular permeability.

Main Results:

  • Microvascular permeability significantly increased during reperfusion in both control and iloprost-treated groups.
  • Iloprost treatment significantly attenuated the rise in vascular permeability compared to controls (4.8 +/- 0.3 vs. 7.3 +/- 0.5 microliters/gm/min).

Conclusions:

  • Iloprost effectively decreases the increase in vascular permeability after skeletal muscle ischemia and reperfusion.
  • Clinical use of iloprost for acute skeletal muscle ischemia warrants further investigation.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...